Part D plans project rebates will increase to 25.3% of total drug costs in their bids for the 2018 benefit year, the recently-released Medicare Trustees Report notes.
Spending on Part D benefits in 2018 is expected to decrease 6% to $94bn because of higher rebates, according to projections in the 2018 Medicare Trustees Report, released June 5.
Part D plans raised rebates projections to 25.3% of total drug costs in their bids for the 2018 benefit year, the report notes. The 2018 bids were submitted to the...
President Trump’s new Executive Order on drug pricing reprises several policy themes from his first administration, including giving the FDA many tasks intended to increase competition in the marketplace.
Germany’s federal health care decision-making body, the G-BA, tells the Pink Sheet that German drug prices are fair and speculation of price rises in the market due to the US MFN policy is fear mongering.
In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.
The FDA is not currently signaling that stringent rules for the process will be relaxed, but the agency's change in approach is notable.
In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.
The FDA is not currently signaling that stringent rules for the process will be relaxed, but the agency's change in approach is notable.
Now that the landmark Pandemic Agreement has finally been adopted, work will start on drafting a pathogen access and benefit sharing system that will be voluntary for use by drug companies.
